Takeda: Neoplasms trials

The registry lists 37 Neoplasms studies with Takeda as lead sponsor. 0 are open to participants now and 24 have results posted.

Phase 1 35Phase 2 4Phase 3 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver ProblemsCompletedNCT03814005Phase 1Results posted
• A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune SystemTerminatedNCT03648372Phase 1/2Results posted
• A Study of Niraparib as Single Agent in Participants With Advanced Solid TumorsCompletedNCT03497429Phase 1Results posted
• A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid TumorsCompletedNCT03420742Phase 1Results posted
• A Study of [14 C]-Pevonedistat in Participants With Advanced Solid TumorsCompletedNCT03057366Phase 1Results posted
• Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of DosesCompletedNCT02467270Phase 2Results posted
• A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic MalignanciesCompletedNCT02412722Phase 1Results posted
• A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic MalignanciesCompletedNCT02327169Phase 1Results posted
• Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid TumorsCompletedNCT02122770Phase 1Results posted
• A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid TumorsTerminatedNCT02045095Phase 1Results posted
• Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver DysfunctionCompletedNCT01912222Phase 1Results posted
• A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic MalignanciesCompletedNCT01899053Phase 1Results posted
• Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid TumorsCompletedNCT01862328Phase 1Results posted
• Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase CCompletedNCT01577758Phase 1Results posted
• Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or LymphomaCompletedNCT01454076Phase 1Results posted
• A Clinical Trial With Intranasal Fentanyl in Cancer Patients With Breakthrough PainCompletedNCT01429051Phase 3Results posted
• Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid MalignanciesCompletedNCT01351350Phase 1Results posted
• Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic MalignanciesTerminatedNCT01179399Phase 1Results posted
• Dose Escalation Study of MLN0128 in Participants With Advanced MalignanciesCompletedNCT01058707Phase 1Results posted
• Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal MalignanciesCompletedNCT01045421Phase 1/2Results posted
• Study of MLN8237 in Participants With Advanced Solid TumorsCompletedNCT00962091Phase 1Results posted
• A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic MalignanciesCompletedNCT00830869Phase 1Results posted
• A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced MalignanciesCompletedNCT00651664Phase 1Results posted
• A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid TumorsCompletedNCT00500903Phase 1Results posted
• A Study of TAK-102 in Adult With Previously-Treated Solid TumorsTerminatedNCT04405778Phase 1
• Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid TumorsWithdrawnNCT04260009Phase 1/2
• Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid TumorsCompletedNCT01765790Phase 1
• Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced Nonhematologic MalignanciesWithdrawnNCT01613261Phase 1
• A Study of TAK-441 in Adult Patients With Advanced Nonhematologic MalignanciesCompletedNCT01204073Phase 1
• Study of TAK-733 in Adult Patients With Advanced Nonhematologic MalignanciesCompletedNCT00948467Phase 1
• Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological MalignanciesCompletedNCT00831896Phase 1
• Study of MLN4924 in Adult Patients With Nonhematologic MalignanciesCompletedNCT00677170Phase 1
• Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological MalignanciesCompletedNCT00660920Phase 1
• A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced MalignanciesTerminatedNCT00652158Phase 1
• A Study of MLN8054 in Patients With Advanced Solid TumorsTerminatedNCT00249301Phase 1
• Ketoconazole Administration: How it is Affected by the Body and Broken Down and How it Acts on the Body When Used With VelcadeCompletedNCT00129207Phase 1
• Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2CompletedNCT00034281Phase 1